Simplified Summary
Sermorelin (GHRH 1-29 NH2) is the N-terminal fragment of human growth hormone-releasing hormone that retains full biological activity at the GHRH receptor. Preclinical research has used sermorelin to study pituitary somatotroph biology, growth hormone secretion dynamics, and the downstream consequences of amplified GH axis activity in laboratory animal models. Its shorter sequence compared to full-length GHRH has made it a convenient research tool for investigating GH-axis biology.
In preclinical endocrinology research, sermorelin has been studied for its ability to stimulate episodic growth hormone release from pituitary somatotrophs through GHRH receptor-mediated cAMP signalling. Animal model studies have examined the pulsatile nature of sermorelin-stimulated GH secretion, its dose-response characteristics, and the relationship between GHRH receptor activity and downstream IGF-1 production in relevant model systems.
Key Findings Reported in Preclinical Models
- Dose-dependent stimulation of growth hormone release in preclinical animal models, with plasma GH concentration measurements documenting acute GH pulses following sermorelin administration.
- GHRH receptor binding and cAMP signalling characterisation in pituitary somatotroph cell culture systems.
- Elevation of circulating IGF-1 levels in animal models following chronic sermorelin dosing, reflecting downstream activation of the GH-IGF-1 axis.
- Effects on bone density and body composition parameters in preclinical growth studies in relevant rodent and animal models.
- Preservation of pituitary somatotroph responsiveness in ageing animal models, with preclinical data examining whether GHRH receptor-mediated GH stimulation is maintained in older animal cohorts.
Introduction
Growth hormone-releasing hormone is the primary hypothalamic regulator of pituitary growth hormone secretion, acting on GHRH receptors expressed on somatotroph cells to stimulate GH synthesis and pulsatile release. Sermorelin was developed as a truncated GHRH analogue and has been used in preclinical research to characterise somatotroph biology, GH secretion dynamics, and the physiological and metabolic consequences of stimulated GH axis activity in animal model systems.
Research Applications
- Hypothalamic-pituitary GH axis research using sermorelin to characterise GHRH receptor pharmacology and somatotroph cell biology in preclinical model systems.
- IGF-1 axis biology research in animal models examining downstream consequences of GHRH-stimulated GH release on liver IGF-1 production and tissue growth responses.
- Ageing and growth hormone biology research in older animal model cohorts examining age-related changes in pituitary responsiveness to GHRH stimulation.
- Body composition and bone biology research in preclinical models examining the anabolic and metabolic consequences of sermorelin-stimulated GH axis activation.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.